Despite acknowledging that a one-size-fits-all treatment duration is suboptimal, the expert consensus is to follow the study protocol. This conservative, evidence-based approach prevails due to the absence of validated biomarkers, like ctDNA, to safely guide treatment de-escalation for individual patients.
A notable trend is patients achieving a strong response to neoadjuvant therapy and then refusing definitive local treatment like cystectomy. Experts caution against this "off-study" approach, as it deviates from the curative backbone of care and undermines the ability to build an evidence base for bladder preservation strategies.
The investigational drug FX-909 uses a PPAR-gamma immunohistochemical biomarker that exhibits a binary pattern: expression is either very high in luminal tumors or very low in basal tumors. This clear distinction could significantly simplify patient selection compared to biomarkers that exist on a continuous spectrum.
The rationale for combining the PPAR-gamma inhibitor FX-909 with other agents goes beyond simple synergy. It's a strategic approach to address intratumoral heterogeneity, where a single tumor can contain both target-positive (luminal) and target-negative (basal-like) cell populations, requiring a multi-pronged attack.
The envisioned registrational trial for the PPAR-gamma inhibitor FX-909 would be a combination study of EV-Pembro plus FX-909 versus EV-Pembro alone. This design mirrors the FORAGER trial but targets a broader luminal population selected by a PPAR-gamma IHC biomarker instead of FGFR alterations.
When pressed on the FX-909 phase 1 study's weaknesses, the discussion reveals that the conclusion of no activity in biomarker-negative patients is based on a very small sample of only seven or eight individuals. This highlights the risk of drawing premature conclusions about a drug's efficacy profile from early-phase data.
While the pivotal EV-302 trial allowed for indefinite Enfortumab Vedotin (EV) treatment, real-world clinical experience shows very few patients reach the two-year mark due to cumulative toxicity. This highlights a major divergence between clinical trial design and practical application, with only about 10% making it that long.